Effect of altering dietary omega-6/omega-3 fatty acid ratios on prostate cancer membrane composition, cyclooxygenase-2, and prostaglandin E2

Clin Cancer Res. 2006 Aug 1;12(15):4662-70. doi: 10.1158/1078-0432.CCR-06-0459.

Abstract

Purpose: To determine whether altering the dietary content of omega-6 (n-6) and omega-3 (n-3) polyunsaturated fatty acids affects the growth of androgen-sensitive prostate cancer xenografts, tumor membrane fatty acid composition, and tumor cyclooxygenase-2 and prostaglandin E(2) (PGE(2)) levels.

Experimental design: Individually caged male severe combined immunodeficiency mice were fed isocaloric 20% kcal fat diets with the fat derived either primarily from n-6 fatty acids (n-6 group) or with the fat consisting of n-6 and n-3 fatty acids in a ratio of 1:1 (n-3 group), and injected s.c. with Los Angeles Prostate Cancer 4 (LAPC-4) cells. Tumor volumes and mouse weights were measured weekly, caloric intake was measured 3 days per week, and tumors and serum were harvested at 8 weeks postinjection.

Results: Tumor growth rates, final tumor volumes, and serum prostate-specific antigen levels were reduced in the n-3 group relative to the n-6 group. The n-3 group tumors had decreased proliferation (Ki67 staining) and increased apoptosis (terminal nucleotidyl transferase-mediated nick end labeling staining). In vitro proliferation of LAPC-4 cells in medium containing n-3 group serum was reduced by 22% relative to LAPC-4 cells cultured in medium containing serum from the n-6 group. The n-6/n-3 fatty acid ratios in serum and tumor membranes were lower in the n-3 group relative to the n-6 group. In addition, n-3 group tumors had decreased cyclooxygenase-2 protein and mRNA levels, an 83% reduction in PGE(2) levels, and decreased vascular endothelial growth factor expression.

Conclusion: These results provide a sound basis for clinical trials evaluating the effect of dietary n-3 fatty acids from fish oil on tumor PGE(2) and membrane fatty acid composition, and serum and tumor biomarkers of progression in men with prostate cancer.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Administration, Oral
  • Animals
  • Apoptosis / drug effects
  • Cell Line, Tumor
  • Cell Membrane / chemistry*
  • Cell Membrane / metabolism
  • Cell Proliferation / drug effects
  • Cyclooxygenase 2 / biosynthesis
  • Cyclooxygenase 2 / drug effects
  • Cyclooxygenase 2 / genetics*
  • Diet*
  • Dinoprostone / analysis
  • Dinoprostone / metabolism*
  • Disease Models, Animal
  • Fatty Acids, Omega-3 / administration & dosage*
  • Fatty Acids, Omega-3 / analysis
  • Fatty Acids, Omega-3 / pharmacology
  • Fatty Acids, Omega-6 / administration & dosage*
  • Fatty Acids, Omega-6 / analysis
  • Fatty Acids, Omega-6 / pharmacology
  • Gene Expression Profiling
  • Humans
  • Male
  • Mice
  • Mice, SCID
  • Predictive Value of Tests
  • Prostatic Neoplasms / chemistry
  • Prostatic Neoplasms / diet therapy*
  • Prostatic Neoplasms / pathology
  • RNA, Messenger / drug effects
  • RNA, Messenger / genetics
  • Reverse Transcriptase Polymerase Chain Reaction / methods
  • Time Factors
  • Transplantation, Heterologous
  • Vascular Endothelial Growth Factor A / drug effects
  • Vascular Endothelial Growth Factor A / genetics
  • Xenograft Model Antitumor Assays

Substances

  • Fatty Acids, Omega-3
  • Fatty Acids, Omega-6
  • RNA, Messenger
  • Vascular Endothelial Growth Factor A
  • Cyclooxygenase 2
  • Dinoprostone